Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinqiao Jingfang Decoction is a Traditional Chinese Medicine (TCM) herbal formula being evaluated for its efficacy and safety in treating influenza A virus infections. Developed by researchers at The First Hospital of Jiaxing, the decoction is formulated based on the "Wei Qi Ying Xue" theory, a diagnostic framework for infectious diseases that categorizes progression into Defense (Wei), Qi, Nutrient (Ying), and Blood (Xue) stages. The formula typically incorporates herbs such as Lonicera japonica and Forsythia suspensa (from Yin Qiao San) along with Schizonepeta and Saposhnikovia (from Jing Fang Bai Du San) to address symptoms by clearing heat, detoxifying, and dispelling wind-pathogens. It is administered orally as a liquid decoction to patients in the early stages of viral infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yinqiao Jingfang Decoction.